# Niagen Bioscience, Inc.: overview

NAGE · Nasdaq · CIK 1386570 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/nage.md) · [Financials](/companies/nage/financials.md) · [Filings](/companies/nage/filings.md) · [Insiders](/companies/nage/insiders.md)

Latest reported revenue: [$29.8m](/filings/0001386570-26-000043.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 4, 2026 (XBRL us-gaap:Revenues, accession 0001386570-26-000043).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [25.6](/filings/0001386570-25-000020.md) | [29.1 d](/filings/0001386570-26-000013.md) | [30.5](/filings/0001386570-26-000030.md) | [31.1](/filings/0001386570-26-000043.md) | [34.0](/filings/0001386570-25-000020.md) | [33.8 d](/filings/0001386570-26-000013.md) | [31.5](/filings/0001386570-26-000030.md) | [29.8](/filings/0001386570-26-000043.md) |
| Gross margin | % | [63.5%](/filings/0001386570-25-000020.md) | [62.5% d](/filings/0001386570-26-000013.md) | [63.4%](/filings/0001386570-26-000030.md) | [65.0%](/filings/0001386570-26-000043.md) | [64.5%](/filings/0001386570-25-000020.md) | [64.1% d](/filings/0001386570-26-000013.md) | [63.5%](/filings/0001386570-26-000030.md) | [64.8%](/filings/0001386570-26-000043.md) |
| Operating margin | % | [6.3%](/filings/0001386570-25-000020.md) | [24.4% d](/filings/0001386570-26-000013.md) | [15.7%](/filings/0001386570-26-000030.md) | [10.2%](/filings/0001386570-26-000043.md) | [12.5%](/filings/0001386570-25-000020.md) | [12.1% d](/filings/0001386570-26-000013.md) | [5.0%](/filings/0001386570-26-000030.md) | [2.4%](/filings/0001386570-26-000043.md) |
| Net margin | % | [7.3%](/filings/0001386570-25-000020.md) | [24.6% d](/filings/0001386570-26-000013.md) | [16.6%](/filings/0001386570-26-000030.md) | [11.6%](/filings/0001386570-26-000043.md) | [13.5%](/filings/0001386570-25-000020.md) | [12.2% d](/filings/0001386570-26-000013.md) | [20.1%](/filings/0001386570-26-000030.md) | [3.2%](/filings/0001386570-26-000043.md) |
| Diluted EPS | $ per share | [0.02](/filings/0001386570-25-000020.md) | not reported | [0.06](/filings/0001386570-26-000030.md) | [0.04](/filings/0001386570-26-000043.md) | [0.05](/filings/0001386570-25-000020.md) | not reported | [0.07](/filings/0001386570-26-000030.md) | [0.01](/filings/0001386570-26-000043.md) |
| Free cash flow | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [67.4](/filings/0001628280-23-006968.md) | [72.1](/filings/0001628280-24-009380.md) | [83.6](/filings/0001628280-25-009774.md) | [99.6](/filings/0001386570-26-000013.md) | [129](/filings/0001386570-26-000013.md) |
| Gross margin | % | [61.5%](/filings/0001628280-23-006968.md) | [59.4%](/filings/0001628280-24-009380.md) | [60.8%](/filings/0001628280-25-009774.md) | [61.8%](/filings/0001386570-26-000013.md) | [64.3%](/filings/0001386570-26-000013.md) |
| Operating margin | % | [(40.1%)](/filings/0001628280-23-006968.md) | [(25.9%)](/filings/0001628280-24-009380.md) | [(6.7%)](/filings/0001628280-25-009774.md) | [7.8%](/filings/0001386570-26-000013.md) | [12.6%](/filings/0001386570-26-000013.md) |
| Net margin | % | [(40.2%)](/filings/0001628280-23-006968.md) | [(23.0%)](/filings/0001628280-24-009380.md) | [(5.9%)](/filings/0001628280-25-009774.md) | [8.6%](/filings/0001386570-26-000013.md) | [13.4%](/filings/0001386570-26-000013.md) |
| Diluted EPS | $ per share | [(0.40)](/filings/0001628280-23-006968.md) | [(0.24)](/filings/0001628280-24-009380.md) | [(0.07)](/filings/0001628280-25-009774.md) | [0.11](/filings/0001386570-26-000013.md) | [0.20](/filings/0001386570-26-000013.md) |
| Free cash flow | $m | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/nage/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $13.3m | 4,184,659 |  | Added +313,040 |
| [SteelPeak Wealth, LLC](/funds/1801868.md) | 2026-06-30 | $11.2m | 3,500,129 |  | Added +127,129 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $6.8m | 2,147,018 |  | Reduced −2,259 |
| [Qube Research & Technologies Ltd](/funds/1729829.md) | 2026-06-30 | $5.2m | 1,625,016 |  | Reduced −89,623 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $4.7m | 1,478,603 |  | Added +133,682 |
| [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $4.1m | 1,283,296 |  | Reduced −122,235 |
| [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $4.0m | 1,262,743 |  | Added +10,784 |
| [ARROWSTREET CAPITAL, LIMITED PARTNERSHIP](/funds/1164508.md) | 2026-06-30 | $3.7m | 1,171,215 |  | Reduced −1,207,222 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $3.7m | 1,166,233 |  | Reduced −55,261 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $3.5m | 1,082,752 |  | Reduced −1,813 |

## Recent filings

[All 934 filings](/companies/nage/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-04 | 16:04 ET | [10-Q](/filings/0001386570-26-000043.md) | Quarterly report, period 2026-06-30 | 0001386570-26-000043 |
| 2026-08-04 | 16:03 ET | [8-K](/filings/0001386570-26-000042.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001386570-26-000042 |
| 2026-06-29 | 16:30 ET | [8-K](/filings/0001386570-26-000035.md) | 5.07 Shareholder vote results | 0001386570-26-000035 |
| 2026-05-06 | 16:01 ET | [8-K](/filings/0001386570-26-000031.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001386570-26-000031 |
| 2026-05-06 | 16:01 ET | [10-Q](/filings/0001386570-26-000030.md) | Quarterly report, period 2026-03-31 | 0001386570-26-000030 |
| 2026-04-29 | 16:02 ET | [DEF 14A](/filings/0001386570-26-000022.md) | Proxy statement, period 2026-06-24 | 0001386570-26-000022 |
| 2026-03-19 | 08:34 ET | [8-K](/filings/0001386570-26-000017.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001386570-26-000017 |
| 2026-03-04 | 16:01 ET | [8-K](/filings/0001386570-26-000014.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001386570-26-000014 |
| 2026-03-04 | 16:01 ET | [10-K](/filings/0001386570-26-000013.md) | Annual report, period 2025-12-31 | 0001386570-26-000013 |
| 2026-02-26 | 07:02 ET | [8-K](/filings/0001386570-26-000003.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001386570-26-000003 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001386570-26-000013.md), filed Mar 4, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/20e53e7a-d8bc-4531-a29b-689d57067bb3)

## About the filer

- CIK: 1386570
- Tickers: NAGE
- Exchange: Nasdaq
- SIC code: 2833 Medicinal Chemicals & Botanical Products
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:38 ET. No prices; not investment advice.